United States — Food and Drug Administration & Kirby McInerney LLP

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.

Kirby McInerney LLP: Kirby McInerney LLP is the law firm representing investors in the securities class action lawsuit against Aldeyra Therapeutics, seeking lead plaintiff appointments and managing the litigation.